Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII.

World J Surg Oncol · 2026 · PMC12918132 · PMID 41588455

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the combination of cetuximab plus TP chemotherapy demonstrated a trend toward improved outcomes, the difference did not reach statistical significance, suggesting a limited incremental benefit.

also in 111,027 other papers

showed a trendno p-value reported

The 2-year OS, PFS, and LFS in this group showed a trend toward improvement compared with the TP chemotherapy alone group, though it had no statistical significance ( P > 0.05).(Fig. 2 D-F).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.